Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: Initial experience in 134 patients-a hypothesis-generating exploratory study

Radiology

Volumn 269, Issue 3, 2013, Pages 857-869

  Catalano, Onofrio A ^a   Rosen, Bruce R ^b   Sahani, Dushyant V ^b   Hahn, Peter F ^b   Guimaraes, Alexander R ^b   Vangel, Mark G ^b   Nicolai, Emanuele ^a   Soricelli, Andrea ^a   Salvatore, Marco ^c  

^a IRCCS SDN   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; IOMEPROL;

ADULT; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER PATIENT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ESOPHAGUS CANCER; FEMALE; GALLBLADDER CANCER; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MIDDLE AGED; MYELOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PANCREAS CANCER; PENIS CANCER; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SARCOMA; SPLEEN CANCER; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TONSIL CANCER; UTERINE CERVIX CANCER; UTERUS CANCER;

CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84890038096     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13131306     Document Type: Article

References (39)

1. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41(8):1369-1379.
2. von Schulthess GK, Schlemmer HP. A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 2009;36(Suppl 1):S3-S9.
3. Delso G, Fürst S, Jakoby B, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med 2011;52(12):1914-1922.
4. Boss A, Bisdas S, Kolb A, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med 2010;51(8):1198-1205.
5. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
6. Padhani AR, Koh DM, Collins DJ. Wholebody diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 2011;261(3):700-718.
7. Sobin LH, Gospodarowicz MK, Wittekind C, et al. TNM classification of malignant tumours. 7th ed. Chichester, West Sussex, England: Wiley-Blackwell, 2010.
8. Holzapfel K, Bruegel M, Eiber M, et al. Characterization of small (?10 mm) focal liver lesions: value of respiratory-triggered echo-planar diffusion-weighted MR imaging. Eur J Radiol 2010;76(1):89-95.
9. Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 2000; 231(5):743-751.
10. Daniels IR, Fisher SE, Heald RJ, Moran BJ. Accurate staging, selective preoperative therapy and optimal surgery improves outcome in rectal cancer: a review of the recent evidence. Colorectal Dis 2007;9(4):290-301.
11. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007;246(3):502-509; discussion 509-511.
12. Antoch G, Stattaus J, Nemat AT, et al. Nonsmall cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003; 229(2):526-533.
13. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348(25):2500-2507.
14. Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18Ffluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001;12(6):825-830.
15. Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga- DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 2008;112(11):2447- 2455.
16. Park JW, Kim JH, Kim SK, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008;49(12):1912-1921.
17. Son H, Khan SM, Rahaman J, et al. Role of FDG PET/CT in staging of recurrent ovarian cancer. RadioGraphics 2011;31(2):569-583.
18. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDGPET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 2007;110(3): 652-659.
19. Mueller-Lisse UG, Mueller-Lisse UL, Meindl T, et al. Staging of renal cell carcinoma. Eur Radiol 2007;17(9):2268-2277.
20. Ozawa Y, Hara M, Sakurai K, et al. Diagnostic accuracy of (18)F-2-deoxy-fluoro-Dglucose positron emission tomography for pN2 lymph nodes in patients with lung cancer. Acta Radiol 2010;51(2):150-155.
21. Sharma P, Kumar R, Singh H, et al. Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence. Clin Nucl Med 2012;37(7):649-655.
22. Schroeder T, Ruehm SG, Debatin JF, Ladd ME, Barkhausen J, Goehde SC. Detection of pulmonary nodules using a 2D HASTE MR sequence: comparison with MDCT. AJR Am J Roentgenol 2005;185(4):979- 984.
23. Yoo HJ, Lee JM, Lee MW, et al. Hepatocellular carcinoma in cirrhotic liver: doublecontrast- enhanced, high-resolution 3.0T-MR imaging with pathologic correlation. Invest Radiol 2008;43(7):538-546.
24. Kirchner J, Kirchner EM, Goltz JP, Lorenz VW, Kickuth R. Prevalence of enlarged mediastinal lymph nodes in heavy smokers: a comparative study. Eur Radiol 2011;21(8):1594-1599.
25. Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol 1985;144(2):261-265.
26. Grubnic S, Vinnicombe SJ, Norman AR, Husband JE. MR evaluation of normal retroperitoneal and pelvic lymph nodes. Clin Radiol 2002;57(3):193-200; discussion 201-204.
27. Brown G, Richards CJ, Bourne MW, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 2003;227(2):371-377.
28. Tiguert R, Gheiler EL, Tefilli MV, et al. Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology 1999;53(2):367-371.
29. Nasu K, Kuroki Y, Nawano S, et al. Hepatic metastases: diffusion-weighted sensitivityencoding versus SPIO-enhanced MR imaging. Radiology 2006;239(1):122-130.
30. Hwang S. Imaging of lymphoma of the musculoskeletal system. Radiol Clin North Am 2008;46(2):379-396, x.
31. Souvatzoglou M, Eiber M, Takei T, et al. Comparison of integrated whole-body [(11)C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging 2013 Jul 2. [Epub ahead of print]
32. Gorospe L, Jover-Díaz R, Vicente-Bártulos A. Spectrum of PET-CT pelvic pitfalls in patients with gynecologic malignancies. Abdom Imaging 2012;37(6):1041-1065.
33. Son H, Kositwattanarerk A, Hayes MP, et al. PET/CT evaluation of cervical cancer: spectrum of disease. RadioGraphics 2010;30(5): 1251-1268.
34. Stolzmann P, Veit-Haibach P, Chuck N, et al. Detection rate, location, and size of pulmonary nodules in trimodality PET/CTMR: comparison of low-dose CT and Dixon- based MR imaging. Invest Radiol 2013; 48(5):241-246.
35. Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 2012;53(6):845-855.
36. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging - version 1.0. Eur J Nucl Med Mol Imaging 2010;37(1):181-200.
37. Chen YM, Huang G, Sun XG, et al. Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan. Nucl Med Commun 2008;29(5):425-430.
38. Cheng G, Torigian DA, Zhuang H, Alavi A. When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging 2013;40(5):779-787.
39. Laffon E, de Clermont H, Begueret H, et al. Assessment of dual-time-point 18F-FDGPET imaging for pulmonary lesions. Nucl Med Commun 2009;30(6):455-461.